This session included ®ve presentations in the areas of pathology of precursor lesions and carcinoma of the prostate, the value of determining neovascularity in the diagnosis and staging of prostate cancer, new`molecular' markers, correlation between pre-and postoperative Gleason scores and a study dealing with transition zone PSA density. The abstracts and talks are summarized in the next few pages.
I-premalignant lesions
Historically, the concept of premalignant lesions of carcinoma of the prostate along with their the natural history and evolution has been poorly de®ned. This is due in part to the wide range of`atypical' epithelial proliferative processes that occur in the gland which have been designated with different and overlapping descriptive terms.
In recent years, two major categories of`atypia' have evolved: the ®rst characterizes a process that takes place within the lining epithelium of pre-existing ducts and acini with cytologic atypia of the lining but usually without proliferation of these units. This entity was de®ned by McNeal and Bostwick 7 and subsequently, Bostwick and Brawer 8 who proposed the term`prostatic intraepithelial neoplasia' (PIN) for this lesion. The other describes alterations in the architecture and distribution of the ducts and acini that typically depicts proliferation and crowding of small acinar structures without cytologic atypia of the lining. Within this category, the one morphologically well de®ned entity is atypical adenomatous hyperplasia (AAH). The rest of the architecturally atypical category, that is, crowded small acini represent a diverse and heterogenous groups of lesions without common features except for the presence of a focus of small crowded acini that can not be con®dently diagnosed as benign or malignant. Most recently the term atypical small acinar proliferation (ASAP) has been used to designate this heterogenous group of lesions. The following is a more detailed discussion of the diagnostic criteria and signi®-cance of HGPIN.
Prostatic intraepithelial neoplasia: origin of prostate cancer
Prostatic intraepithelial neoplasia (PIN) is best characterized as a neoplastic transformation of the lining epithelium of prostatic ducts and acini. By de®nition, this process is con®ned within the epithelium therefore, intraepithelial. PIN is divided into low and high grades based on the degree of architectural complexity and more importantly, on the extent of cytologic abnormalities. High grade PIN (HGPIN) is the more uniformly atypical morphologic manifestation of this spectrum and is the lesion that has been shown to have numerous links to prostate cancer. The lesion is characterized by cytologically malignant cells lining the glandular units of the prostate. While the architectural complexity of the lining can vary and assume different patterns, the individual cells of HGPIN are almost uniformly enlarged with increased nuclear/cytoplasmic ratio, therefore showing less variation in nuclear size than that seen in low grade PIN. The signi®cance and importance of recognizing, diagnosing and managing HGPIN has evolved remarkably during the last decade. There have been mounting data linking the lesion to prostate cancer and advocating its role as the main premalignant lesion of the prostate. The followings represent a summary of the categories of associations between cancer and HGPIN.
Epidemiologically
The prevalence of both HGPIN and cancer increases with advancing age. Prostate cancer is more prevalent in prostate glands with HGPIN. HGPIN in its diffuse form appears at a younger age in African ± Americans. 
Morphologically

Clinical aspects and implications
HGPIN is an indicator for the presence of carcinoma (50% on repeat biopsy). HGPIN is sensitive to androgen ablation therapy.
While the ®rst three`links' are important in furthering the understanding the potential role for HGPIN in the carcinogenesis of prostate cancer, the fourth item represents the more immediate, clinical care issue associated with the importance of the diagnosis and follow up of this lesion and the potential utility of its susceptibility to androgen withdrawal.
In conclusion, why is it important that this lesion is recognized and reported by the surgical pathologist? The main reason for that is what we know about the role of HGPIN as a marker for the presence of prostate cancer. When HGPIN is identi®ed on a needle biopsy without concurrent prostate cancer, the likelihood of a subsequent biopsy to harbor carcinoma is approximately 50%. Additionally, as shown above also, there is data to suggest that the prevalence and extent of HGPIN is higher in ethnic groups that are known epidemiologically to have higher incidence and mortality due to prostate cancer. Therefore the lesion can serve as a marker for high risk groups and perhaps provide a target for intervention and chemoprevention trials. Finally, within the wide biological spectrum and clinical behavior of prostate cancer, there are indications that HGPIN is a lesion that shows more links to the potentially more aggressive cancers than those that are more likely to remain indolent.
Pathology of prostate cancer WA Sakr 
Epidemiologic and clinical considerations
In spite of recent decline in the number of new cases diagnosed annually, prostate cancer continues to be the most common cancer in adult men and the second leading cause of cancer deaths. The clinically diagnosed disease remains remarkably less common than the extremely prevalent`latent' cancer discovered during post mortem examination. Both manifestations of prostate cancer increase progressively with advancing age. The racial and geographic differences in the incidence and mortality of this disease continues to represent a most signi®cant epidemiologic and management challenge.
Gross and microscopic pathology
Most prostate cancers (over 80%) develop in the peripheral zone of the gland with 10 ± 20% arising in the transition zone. The tumors may be circumscribed (nodular) though not encapsulated or diffuse with poorly de®ned margins. Classically the tumors are said to have a yellow color though most often they are grey or white while the yellow color is most often seen in tumors of transition zone origin. More than 95% of malignant prostatic tumors are adenocarcinomas (gland forming). While the minimal diagnostic criteria for well differentiated adenocarcinoma remain controversial but most use the criteria established by Gleason. These comprise a uniform small glands that are lined by a single layered epithelium with prominent nucleoli. Other features that are helpful to support the diagnosis of cancer although not diagnostic on their own include the presence of crystalloids and/or acid mucin, perineural in®ltration by the malignant glands is another useful diagnostic feature of cancer.
The role of pathology
After establishing the diagnosis of carcinoma, the pathologist helps in assessing the biologic potential of prostate cancer and assisting the urologist and/or the radiation or medical oncologist in the management of the individual patient. This is achieved by accurately assessing the traditional parameters of stage and grade which continue to be the corner stone in the clinical management and in exploring and verifying the role of additional`prognostic markers utilizing the evolving molecular techniques.
Staging of prostate cancer
Pathologic stage remains arguably the most powerful predictor for tumor behavior and patient outcome. The AJCC-TNM is a clinical staging system which in its most recent revision has been partially translated into a pathologic staging system with the designation p preceding the particular stage category. The applicability of the pT categories is largely restricted to radical prostatectomy specimens. Certain issues with respect to the TNM are worth mentioning. The incidentally discovered clinical T1 category has its pT1 correlate in the transurethral resection specimen, with no corresponding pathologic correlate in the radical prostatectomy specimen (where all tumors are pT2 or higher). Within the pT2 category of organ con®ned PC, there is no data to indicate that the subcategories of pT2a, pT2b, and pT2c in¯uence PSA recurrence and, therefore, these are all included in the pT2 category. Cancer extending out of the gland, including the invasion of the seminal vesicle constitutes stage T3 disease. Based on radical prostatectomy data that unilateral and bilateral extraprostatic extension respectively, show no difference in PSA recurrence, the 1997 AJCC/ TNM includes both groups in the pT3a category with seminal vesicle invasion being de®ned as pT3b.
Some prostate cancers in radical prostatectomy specimens extend to the surgical margins with no histologic evidence of extraprostatic extension. This category has been designated as pT2 (organ con®ned disease but with positive surgical margins). It is important to address the clinical category T1c which signi®es prostate cancers that are detected because of PSA elevation in the absence of abnormal rectal examination or ultrasound ®ndings. This group translates into a wide spectrum of pathologic categories that range locally from pT2 to pT4 and can have nodal spread or even distant metastases in rare cases. This is a clinical staging system and as such is only partially interpretable as a pathologic staging system (particularly in the radical prostatectomy specimen)
Grading prostate cancer
Carcinoma of the prostate is heterogeneous tumor system in terms of its histologic differentiation. Most prostatic cancers are multifocal with signi®cant variations in tumor grade between anatomically separate tumor foci and within the same tumor nodule where neoplastic components with a spectrum of histologic differentiation in a close microscopic proximity are often identi®ed. These properties can result in signi®cant sampling errors when the grade is established from limited tissue specimens (usually needle core biopsies). After decades of developing and testing multiple grading schemas for this cancer, the Gleason system has gained the widest acceptance.
This system is based on the architectural growth patterns of the tumor that are classi®ed into 5 grade categories with the key concept of`quantifying' the neoplastic components of prostatic carcinoma. It is important to emphasize that the`lumping' of this quantitative system into three categories of well, moderately, and poorly differentiated tumors corresponding to histologic scores 2-3-4, 5-6-7 and 8-9-10 is indeed misleading. The central group encompasses tumors with remarkably different biological aggressiveness ranging from the low malignant potential of score 5 to the moderate course of score 6 and the higher level of malignant behavior expected for score 7. Furthermore, we have demonstrated that even in the single Gleason score of 7, the proportion of Gleason grade 4 component in patients correlates signi®cantly with advanced pathologic stage, DNA aneuploidy, cellular proliferation and with a trend for higher biochemical recurrence.
In conclusion, a well documented pathologic stage and accurately determined Gleason score remain the most powerful indicators of patients outcome in this malignancy. Prostate cancer progression as evidenced by local recurrence, distant metastases and ultimate survival decreases as pathologic stage changes from organ con®ned disease, to that which extends to the surgical margins and or extraprostatic tissue, to cancers with seminal vesicle invasion or nodal or worse, systemic metastases. Similarly, there is statistically signi®cant and strong difference in the biochemical recurrence and the survival of patients with the Gleason scores of`6, 7 and b 8 respectively.
Neovascularity; microvessel density: a new tool for staging and prognosis
M Brawer
Following the discussions on traditional prognosticators of stage and grade and the bene®ts of combining them in different nomograms (serum PSA level, tumor grade on the biopsy, along with the extent of cancer on the biopsy), clinical stage and imaging studies etc., this presentation addressed a novel approach aimed at improving the prediction of organ con®ned prostate cancer.
Microvessel density (MVD), is a relatively newer marker in this arena and may help supplementing the value PSA level and biopsy Gleason score in improving the prediction of extracapsular disease. Recruiting and making' new blood vessels from the host is an essential requirement for the growth of most solid tumors beyond 1 cm 3 . This is achieved with the aid of angiogenesis promoters of which at least eight angiogenic polypeptides have been described and sequenced. Evaluating micro vessel distribution has been facilitated by studies of radical prostatectomy specimens in which microvessel density was shown to increase from normal prostate tissue (which tends to have microvessels that are oriented along the epithelial basement membrane of benign glands), to adenocarcinoma which, contains a high density of microvessels, generally twice that of adjacent normal benign tissue. The microvessels associated with neoplasia are heterogeneous in size and shape. In moderately and poorly differentiated cancers, the microvessels are no longer aligned with glands but appear in a disorganized pattern throughout the stroma. An intermediate degree of angiogenesis is found in the vicinity of Prostatic intraepithelial neoplasia (PIN).
Microvessel density and staging
The author and collaborators have shown a strong correlation between MVD and pathological stage in radical prostatectomy specimens. With a 100% speci®city, 100% positive predictive value of 100 and a sensitivity of 44.4% (at a cut-off of 120 vessels/mm2), these investigators were able to segregate organ-con®ned from advanced prostate cancer. The combination of a age and Gleason score predicted pathologic stage 75% of the time in a multi-variate analysis. While adding serum PSA levels to the model did not improve the predictive ability, adding MVD increased the overall accuracy to 87.5%. Interestingly, the authors indicated that there was a relative homogeneity in microvessel density in different tumor areas from one individual minimizing the negative effect of establishing MVD from a limited tissue sample, that is, needle biopsies.
A recent multi-institutional study of 186 patients who were treated by radical prostatectomy authored by Bostwick et al 32 reported that determining MVD of the needle biopsy specimens was able to signi®cantly improve the ability to preoperatively predict extracapsular extension when combined with serum PSA and Gleason score. These authors used immunoperoxidase staining for the MVD determination of each needle biopsy core containing cancer and`optimized' by an automated algorithm that enhanced the difference between stained vessels and background. The authors found that extracapsular tumor extension correlated signi®cantly with higher microvessel density counts, higher Gleason scores and higher serum PSA levels. Moreover, a logistic regression analysis showed each one of these factors to be an independent predictor of extracapsular extension. In a`probability table' based on this study, the authors demonstrated the utility of adding MVD to the table to maximize the predictability of pathologic stage. According to the table, a patient with a serum PSA of 8 ng/mL, a Gleason score of 8, and an optimized microvessel density count of 500 in a needle biopsy specimen has an estimated 93% chance of extra-prostatic extension of cancer. This can help in designing the optimal management strategies for patients newly diagnosed with clinically localized prostate cancer.
Microvessel density and prognosis
At least in subsets of patients with prostate cancer, MVD may add prognostic information to the traditional parameters of stage, grade, PSA etc. The author of this presentation and colleague have shown that MVD predicts progression in men with pathologic State C(pT3) disease treated with radical prostatectomy. Hall and colleagues 32b found a positive association between MVD and the likelihood that prostate cancer will recur after irradiation therapy. Silberman et al, 32a reported that MVD is an independent signi®cant predictor of progression after radical prostatectomy for tumors with a Gleason score of 5 ± 7. Gettman et al 34 however found no signi®-cant correlation between MVD and the progression of organ con®ned prostate cancer. More recently, Bettencourt et al 49 in a study of 149 radical prostatectomy specimens, have found that mean MVD count correlated signi®cantly with tumor nuclear grade, Gleason sum and pathological stage. The authors also reported that using a Cox survival analysis showed that MVD is signi®cantly related to time recurrence when considered as a continuous and as a dichotomous variable. The 5 y recurrence-free survival was signi®cantly higher for patients with a count less than 90 (71%) than for those with a count 90 or greater (51%). This signi®cance was maintained after controlling for stage, Gleason sum, race and nuclear grade.
Microvessel density technology
Most investigators have used immunohistochemical staining for factor VIII or CD34 to lable microvessels in formalin-®xed, paraf®n-embedded tissue samples from a diagnostic biopsy or a radical prostatectomy specimen. Precise quanti®cation requires a rigorous image-analysis technique. This can be done by eye, but computerized methods signi®cantly speed the process. The technology is not widely available although a number of academic centers and commercial collaborators have been developing assays that allow unstained sections of biopsy cores to be forwarded to a reference laboratory for MVD analysis.
Conclusions
Similar to other tumor systems, neovascularity in carcinoma of the prostate, represent an important requirement in the process of tumor growth and progression in the prostate. There are data strongly supporting that MVD correlates with pathologic stage therefore suggesting a role for this technology in designing the appropriate treatment course. The data correlating MVD with prognosis following radical prostatectomy are less consistent although this factor may be relevant in subsets of patients, namely those with stage pT3 and patients with Gleason score of 5 ± 7.
New prognostic markers: P53, bcl2 and others JW Moul
In spite of the favorable stage migration witnessed during the 1990s, approximately 50% of the patients undergoing radical prostatectomy will have at least microscopic evidence of extraprostatic disease and of those, close to 40% will experience disease progression. The surrogate endpoint used to determine progression or`failure' following surgery or radiation therapy is biochemical recurrence de®ned according to different institutions/investigators as either any detectable serum PSA after therapy, a single value greater than 0.4 or 0.5 ng/ml or two consecutive values equal to or greater than 0.2 ng/ml. As discussed earlier, traditional parameters of pretreatment PSA levels, stage and Gleason score all correlate signi®cantly with the likelihood of recurrence. While many of these markers show convincing correlations with traditional parameters such as stage and grade, the data indicating an independent prognostic signi®cance variable although some are promising.
Models for prediction of PSA failure
Most recently investigators have combined prognostic variables into models or equations used to predict the likelihood of recurrence. Partin and Osterling 39 were the ®rst investigators to develop a simple biostatistical model equation that categorized post-radical prostatectomy patients into three risk groups (low, intermediate, and high risk) for likelihood of serological failure. In this model, a multivariate regression analysis revealed only three variables were included in the ®nal model to adequately select for high-risk patients after surgery. A sigmoidal transformation of PSA, prostatectomy, Gleason score and, specimen con®nement (margin status).
The author's group presented a second model to predict PSA recurrence after radical prostatectomy combining the age, race, preoperative PSA, postoperative Gleason score, postoperative nuclear grade, pathological stage and the biomarkers p53, bcl-2, and Ki-67 using Cox multivariable regression analysis. In 132 patients with a mean follow-up of 5.4 y, they found that the stage and both p53 and bcl2 were signi®cant predictors of recurrence while Gleason score was not. Subsequently, the authors tested the signi®cant variables on three groups divided by race and pathological stage and biomarker status.
The authors concluded that in their cohort of patients and their lab settings, p53 and bcl2 immunohistochemical staining of the radical prostatectomy specimen was able to add independent prognostic information to already existing factors. They acknowledge however, that the speci®cs of their report, including the methodology and the population studied may not be applicable to the general clinico/laboratory conditions of what the authors call the`real world' conditions. Accordingly the authors studied a group of 378 patients from their institution and 91 patients from a separate hospital to serve as a validation cohort. We performed similar modeling, as above, using only widely available prognostic factors. The authors applied the same design used in their own cohort to this mixed study population but restricted the analysis to the traditional variables that signi®cantly correlated with recurrence. The model calculates the relative risk of recurrence, Rr, as: Rr exp[(0.51 6 Race) (0.12 6 1PSAST) (0.25 6 postop Gleason) (0.89 6 organ con®ned ). Race was de®ned as`1' if the patient was African ± American or`0' if Caucasian or other. PSAST (sigmoidal transformation of PSA) was calculated using the equation: PSAST 1 0/ (1 e6.8704 ± 0.9815 6 PSA).
Postoperative Gleason sum (2 ± 10) was de®ned as a continuous integer value. Organ con®ned (no capsular penetration) was de®ned as`0,' whereas, non-organ con®ned (capsular extension and/or positive margins) was de®ned as`1.' They have placed this traditional model equation on their urologic clinic local area computer network and each clinician can enter the race, PSA, Gleason score sum, and pathologic stage into the program prospectively, and the computer will automatically calculate the Rr and show the recurrence information. A statistically signi®cant recurrence rate was evident separating the low, intermediate and high risk groups as identi®ed above.
Finally, it may be important to emphasize two points that are relevant to the discussion of the role of biomarkers in prostate carcinogenesis and prognosis. Firstly, it is somewhat dif®cult to draw the distinction between the role of a marker in certain pathways of carcinogenesis and its potential utility as a prognosticator. This overlap often results from the appropriate attempts to correlate the observations of a particular molecular experiment with those of clinically established prognostic parameters.
Secondly, with the changing aspects of prostate cancer in the late 1990s, the majority of patients are diagnosed with clinically localized disease and an increasing proportion of them will have a pathologically organ con®ned tumor with smaller volume than physicians used to encounter several years ago. Rather than in this`earlier' disease setting, the majority of the molecular data and particularly abnormalities, have been generated from advanced prostate cancer. The reason(s) for this are likely to be related to the more readily available tissues from more advanced disease and the intense effort and expertise required to identify and isolate samples from small tumors and preinvasive neoplasia. The wide interest in this area coupled with the evolving advances in tissue microdissection and molecular techniques would be expected to overcome these hurdles.
Finally, with respect to the prognostic value of some of the parameters discussed, it is worth referring the reader to the criteria proposed by the college of American Pathologists for the evaluation of prognostic markers and to reviews addressing the statistical analysis of prognostic marker studies.
Pre-and postopertaive Gleason scores R Donohue
This presentation offers additional and potentially controversial data on a timely topic that have been addressed previously by several investigators, namely, the correlation between the biopsy and the radical prostatectomy Gleason score. The authors compared the Gleason scores of 330 biopsies with their corresponding, whole mounted radical prostatectomy specimens. The results are shown in the table below:   pre-op  post-op   Gleason  2  14  11  Gleason  3  15  14  Gleason  4  77  50  Gleason  5  76  87  Gleason  6  72  35  Gleason  7  42  92  Gleason  6  20  33  Gleason  9  12  7  Gleason  10  2  1 The authors found only 27% agreement between the Gleason score of the biopsy and that of the radical prostatectomy, while in 44% of the cases, the score of the radical specimen was higher and in 24% it was higher by 2 or more scores. The score of the radical specimen was lower than that of the corresponding biopsy in 29% of the cases and in 12% it was lower by 2 or more scores. As expected, the authors found signi®cant correlation between the Gleason score and the ®nal pathologic stage of the radical prostatectomy.
Two aspects of this data are somewhat different from a number of published series. The ®rst concerns the correlation between the Gleason score of the biopsy and that of radical prostatectomy specimen. Compared to a relatively low ratio of 27% of the cases having identical Gleason scores for the biopsy and the radical specimen reported by the authors, other series indicate a signi®cantly higher corresponding rates. Although the range is wide, with a single study reporting a 28% identical scoring rates, most investigators have an identical score for biopsies and radical specimens that ranges between 31 ± 59%. Second and possibly related to the ®rst point, the Gleason score distribution in the author's biopsy series is remarkably tilted towards the well to moderately differentiated carcinoma. Nearly one third (32%) of the biopsies in the series presented had a Gleason score of`4. This is an unusually high proportion of low grade tumors when compared to most contemporary series in which the percentage of such cases are in the single digits.
It is important to emphasize the necessity of incorporating all available clincopathological data in designing the optimal treatment options for patients with prostate cancer including pre-op PSA, age, clinical stage and Gleason score. While it is appropriate not to consider the latter in isolation, it has been repeatedly evident from numerous studies that Gleason score of the biopsy remains a corner stone in this decision making process.
Transition zone PSA density CC Schulman
The utility of prostate-speci®c antigen (PSA) in distinguishing benign prostatic hyperplasia (BPH) from carcinoma in patients with intermediate serum PSA levels (below 10 ng/ml) can be problematic. This presentation describes the methods and bene®ts of measuring the PSA density of the transition zone of the prostate (PSA ± TZ). It is recognized that in patients with levels below 10 ng/ml there is a signi®cant overlap between BPH, and prostate cancer. Since the two processes have a similar age distribution, PSA levels below 10 ng/ml lacks suf®cient sensitivity and speci®city to reliably distinguish them. More than 60% of patients biopsied based PSA level of 4 ± 10 ng/ml have no evidence of prostate cancer following pathologic evaluation of the biopsy.
The authors demonstrated that determining prostate speci®c antigen density of the transition zone (PSA ± TZ) represent a very effective parameter for prostate cancer prediction. This measurement relates the serum PSA level to the volume of the transition zone of the gland since PSA leakage from the transition zone harboring BPH results almost exclusively from the BPH component of this zone. Previous reports have shown that PSA ± TZ has a very high sensitivity and speci®city for prostate cancer prediction from a single test, and is more accurate than total prostate PSA density in men with PSA levels 10 ng/ml. Finally, the PSA ± TZ was statistically higher in patients with prostate cancer than in those with BPH.
In this presentation, the authors summarized the results of determining PSA ± TZ prospectively in 648 men with serum PSA levels`10 ng/ml. The patients underwent a set of ultrasound-guided systematic sextant biopsies which, if negative, were followed by a second six weeks later to ensure their benign status. The transition zone and whole prostate volumes were calculated using the prolate ellipsoid formula. Following biopsy evaluation, 248 patients (38%) were diagnosed with prostate cancer while the remaining 400 patients (62%) were found to have benign histologies. Similar to the ®ndings of a previously reported retrospective study, the authors used a cut-off value of 0.35 ng/ml/cm3 for PSA ± TZ. Considering the sensitivities, speci®cities and positive predictive values, PSA ± TZ was the most powerful predictor of prostate cancer compared with all other parameters, using both univariate and multivariate analyses.
The ®ndings of this study are in accordance with previous results con®rming the effectiveness of PSA±TZ as a predictor of prostate cancer in patients with serum PSA levels`10 ng/ml. While the authors have used a calculated cut-off value of PSA±TZ for the highest sensitivity and speci®city of 0.35 ng/ml/cm3, they believe that a cut-off value of 0.20 ng/ml/cm3 would be suf®cient for clinically relevant practice. On the other hand, the study acknowledges that PSA ±TZ may not be as effective in the detection cancers present in a very small prostate gland which are common in screened populations. Therefore they recommended systematic sextant biopsies to exclude the presence of carcinoma for all patients presenting with a PSA±TZ b 0.35 ng/ml/cm3. Finally however, It is important to mention that other investigators have indicated a lack of use for PSA±TZ in the prediction of prostatic carcinoma.
